---
schema_version: "secwatch.filing_event.v1"
accession: "0001606498-23-000023"
form_type: "8-K"
ticker: "AVNS"
cik: "0001606498"
company_name: "AVANOS MEDICAL, INC."
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T11:40:16.866935+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Avanos Medical appoints Dr. Lisa Egbuonu-Davis to board of directors

## Summary
- Dr. Egbuonu-Davis appointed as independent director effective March 6, 2023; serves on Compliance and Governance Committees.
- She receives $70,000 annual cash retainer, $7,500 Compliance Committee fee, $5,000 Governance Committee fee, and $190,000 in RSUs.
- Board now comprises six directors: five independent, two women, one ethnically diverse.
- Egbuonu-Davis is VP Medical Innovations at DH Diagnostics (Danaher affiliate); previously VP at Sanofi and roles at Pfizer.

## SEC filing metadata
- accession: 0001606498-23-000023
- form_type: 8-K
- ticker: AVNS
- cik: 0001606498
- company_name: AVANOS MEDICAL, INC.
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1606498/000160649823000023/0001606498-23-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1606498/000160649823000023/avns-20230228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001606498-23-000023
- JSON: https://secwatch.observer/filing/0001606498-23-000023.json
- Plain text: https://secwatch.observer/filing/0001606498-23-000023.txt

## Key facts
- Executive change
  Dr. Lisa Egbuonu-Davis was appointed as Director at AVANOS MEDICAL, INC..
  - Action: appointed
  - Role: Director
  source text: On February 28, 2023, the Board of Directors (the “Board”) of Avanos Medical, Inc. (the “Company”) appointed Dr. Lisa Egbuonu-Davis to the Board, effective March 6, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1606498/000160649823000023/0001606498-23-000023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.